Colette M. Gaillard

Belfield, L, Ireland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.

Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: December 23, 2025

Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final report.

Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final report.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: December 23, 2025

Specific thresholds of circulating antibody titers predict against infection and reduced disease severity in SARS-CoV-2 close contacts.

Specific thresholds of circulating antibody titers predict against infection and reduced disease severity in SARS-CoV-2 close contacts.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: January 20, 2025

Associations between type III interferons, obesity and clinical severity of COVID-19.

Associations between type III interferons, obesity and clinical severity of COVID-19.

Journal: Frontiers in immunology
Published: October 24, 2024

Evidence linking cadmium and/or lead exposure to immunomodulatory effects in mammals based upon an adverse outcome pathways approach, and research perspectives.

Evidence linking cadmium and/or lead exposure to immunomodulatory effects in mammals based upon an adverse outcome pathways approach, and research perspectives.

Journal: Chemosphere
Published: September 23, 2024

Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.

Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.

Journal: Frontiers in immunology
Published: June 07, 2024

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: March 27, 2024

Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis.

Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis.

Journal: Heliyon
Published: March 14, 2024

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).

Journal: Vaccine
Published: June 04, 2023

Associations between host microbiome and inflammation suggest role for host microbiome in driving COVID-19 disease severity.

Associations between host microbiome and inflammation suggest role for host microbiome in driving COVID-19 disease severity.

Journal: Microbes and infection
Published: April 12, 2023

Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time.

Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time.

Journal: Nature communications
Published: August 10, 2022

Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination.

Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination.

Journal: Journal of immunological methods
Published: April 27, 2022
Showing 1-12 of 13

Last Updated: 09/26/2026